Rapid infectious disease test ARIES® GBS

pregnancypneumoniagroup B streptococcus

The ARIES® GBS Assay detects Streptococcus agalactiae, also known as Group B Streptococcus (or GBS), from Lim broth-enriched vaginal-rectal specimen swabs obtained from pregnant women using the ARIES® System. Infection with GBS is one of the most important infectious causes of neonatal morbidity and mortality, and can cause meningitis, pneumonia, and septicemia in newborns and their mothers. About 12–27% of pregnant women harbor GBS in their rectum or vagina.1 Most women colonized with GBS do not have symptoms; however, GBS can be transmitted to the newborn during delivery. In the US, GBS is the leading cause of meningitis and sepsis in a newborn’s first week of life.2 The ARIES® GBS Assay Offers: Robust Performance: Integrated sample processing and PCR deliver sensitive results that enable clinicians to implement appropriate treatment strategies in a clinically actionable timeframe. Ease of Use: By using the sample-to-answer ARIES® workflow, detecting antepartum GBS colonization in pregnant women is accessible to labs of all sizes. Full Integration: The ARIES® GBS Assay enables labs to automate all aspects of testing—from sample preparation through analysis. Reduced User Error: Internal barcode scanning matches samples to cassettes, enabling position independent results no matter where each cassette is placed. Additionally, reduce data input errors with electronic ordering through bidirectional laboratory information system (LIS) connectivity. Performance of the ARIES® GBS Assay The performance of the ARIES® GBS Assay was evaluated using excess leftover de-identified Lim broth cultures from women in their 35th–37th week of pregnancy,